Abstract:Within a few years after the first successful clinical use of penicillin, investigations were conducted in animal infection models to explore a range of factors that were considered likely to influence the antibacterial response to the drug. Those studies identified that the response was influenced by not only the total daily dose but also the interval between individual doses across the day, and whether penicillin was administered in an intermittent or continuous manner. Later, as more antibiotics were discovered and developed, antimicrobial pharmacologists began to measure antibiotic concentrations in biological fluids. This enabled the linking of antibacterial response at a single time point in an animal or in vitro infection model with one of three summary pharmacokinetic (PK) measures of in vivo exposure to the antibiotic. The summary PK exposure measures were normalised to the minimum inhibitory concentration (MIC), an in vitro measure of the pharmacodynamic (PD) potency of the drug. The three PK-PD indices (ratio of maximum concentration to MIC, ratio of area under the concentration-time curve to MIC, time concentration is above MIC) have been used extensively since the 1980s. While these MIC-based summary PK-PD metrics have undoubtedly facilitated the development of new antibiotics and the clinical application of both new and old antibiotics, it is increasingly recognised that they have a number of substantial limitations. In this article we use a historical perspective to review the origins of the three traditional PK-PD indices before exploring in detail their limitations and the implications arising from those limitations. Finally, in the interests of improving antibiotic development and dosing in patients, we consider a model-based approach of linking the full time-course of antibiotic concentrations with that of the antibacterial response. Such an approach enables incorporation of other factors that can influence treatment outcome in patients and has the potential to drive model-informed precision dosing of antibiotics into the future.

[Antimicrobial Dosing Individualization Based on Pharmacokinetic/Pharmacodynamic Evaluation, Considering Factors of "Patient", "Site of infection" and "Microorganism"]

Progress on pharmacokinetics/pharmacodynamics of antimicrobial agents

Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem in CKD and Hemodialysis Individuals

Optimizing the anti-infection therapy by the PK/PD theory

Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape

Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review

Antibacterial Pharmacokinetics/pharmacodynamics and Optimizing Treatment of Nosocomial Pneumonia

Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment

Individualized antibiotic dosage regimens for patients with augmented renal clearance

The Application of Population Pharmacokinetic Model to Individualized Antibiotic Therapy

Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant Staphylococcus aureus Infected Patients

Application of pharmacological principles to dosage design of antimicrobial drugs

Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy

The Puzzle of Antibiotic Therapy in the Context of Individualization of Decision Making

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

Use of Pharmacodynamic Principles to Optimise Dosage Regimens for Antibacterial Agents in the Elderly

Application of PK/PD Parameters in Selection of Antibiotic Regimes for Patients with Multi-Drug Resistant Bacterial Infection

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials

Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward

In silico evaluation of a beta-lactam dosing guideline among adults with serious infections